SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
| Autor: | Yizhuo Qin1, Yuyin Lu1, Ruiqi Wang1, Wenbao Li2 wbli92128@yahoo.com, Xianjun Qu1 qxj@sdu.edu.cn |
|---|---|
| Zdroj: | BioScience Trends. Oct2013, Vol. 7 Issue 5, p237-244. 8p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|